Results from a Phase 3 clinical trial, TOURMALINE-MM2, evaluating the addition of Takeda Pharmaceutical’s (TAK +2.3%)
Ninlaro (ixazomib) to Celgene’s Revlimid (lenalidomide) and
dexamethasone in newly diagnosed transplant ineligible multiple myeloma
(MM) patients came up short of expectations.
Specifically, the ixazomib triplet extended median
progression-free survival (PFS) compared to the doublet therapy (35.3
months versus 21.8 months) but the separation fell short of statistical
significance (p=0.073).
No new safety signals were observed.
The data will be submitted for presentation at a future medical conference.
The FDA approved Ninlaro in November 2015 for MM patients who have received at least one prior line of therapy.
https://seekingalpha.com/news/3550147-takedas-ninlaro-shows-less-expected-effect-in-first-line-multiple-myeloma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.